RxDoctor Payments Data

Felipe Samaniego

Medical Oncology · Houston, TXNPI 1871675249

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,055 of the $7,212 with a category attached, or 97.8%. Imbrium Therapeutics L.p. accounts for 77.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $5,591 and has fallen 98.8% since, to $65 in 2022.

$7,212in general payments, 2019–2025

Across 6 payments — averaging $1201.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Imbrium Therapeutics L.p.$6K
  • Otsuka Pharmaceutical Co., Ltd.$1K
  • TG Therapeutics, Inc.$65
  • Seagen Inc.$55
  • Bristol Myers Squibb$24
  • Pfizer$13
$2,138,369in research payments, 2019–2025

Across 119 payments — averaging $17,969 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Co., Ltd.$1.1M
  • Acerta Pharma LLC$344K
  • Bristol Myers Squibb$183K
  • TG Therapeutics, Inc.$125K
  • Janssen Research & Development, LLC$118K
  • Takeda Pharmaceuticals U.S.A., Inc.$87K
  • plus $137K from 6 others

What the payments were for

  • Consulting fees$7,05598%
  • Food & beverage$1021%
  • Education$551%

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,212 in reported general payments places this provider in the 55th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Other medical oncology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →